Basic HTML Version
VOLUME 9 NUMBER 2 • JUNE 2012
65
SA JOURNAL OF DIABETES & VASCULAR DISEASE
RESEARCH ARTICLE
Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D.
3.
Modification
of low density lipoprotein by endothelial cells involves lipid peroxidation and
degradation of low density lipoprotein phospholipids.
Proc Natl Acad Sci USA
1984;
81
: 3883–3887.
Van Tits L, de Graaf J, Toenhake H, van Heerde W, Stalenhoef A.
4.
C-reactive protein
and annexin A5 bind to distinct sites of negatively charged phospholipids present
in oxidized low-density lipoprotein.
Arterioscler Thromb Vasc Biol
2005;
25
: 717–
722.
Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K,
5.
et al
.
The association of C-reactive protein with an oxidative metabolite of LDL and its
implication in atherosclerosis.
J Lipid Res
2007;
48
: 768–781.
Torzewski J, Torzewski M, Bowyer DE, Fröhlich M, Koenig W, Waltenberger J,
6.
et al
.
C-reactive protein frequently colocalizes with the terminal complement complex in
the intima of early atherosclerotic lesions of human coronary arteries.
Arterioscler
Thromb Vasc Biol
1998;
18
: 1386–1392.
Rifai N, Ridker PM. High sensitivity CPR protein: A novel and promising marker of
7.
coronary heart disease.
Clin Chem
2001;
47
: 403–411.
Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A,
8.
et al
. C-reactive
protein, a sensitive marker of inflammation, predicts future risk of coronary heart
disease in initially healthy middle-aged men: results from the MONICA (Monitoring
Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984
to 1992.
Circulation
1999;
99
: 237–242.
Iughetti L, Volta C, Maggi E, Palladini G, Perugini C, Bellomo G, Bernasconi S.
9.
Circulating antibodies recognizing oxidatively modified low-density lipoprotein in
children.
Pediatr Res
1999;
45
: 94–99.
Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF.
10.
Anti-oxidized low-density
lipoprotein antibodies in patients with coronary heart disease and normal healthy
volunteers.
Int J Clin Lab Res
1993;
23
: 95–101.
Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G.
11.
Autoantibodies
against oxidatively modified low-density lipoproteins in NIDDM.
Diabetes
1995;
44
: 60–66.
Shaw PX, Hörkkö S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, Witztum
12.
JL. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic
clearance, and protective immunity.
J Clin Invest
2000;
105
: 1731–1740.
Hörkkö S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G,
13.
et al
.
Monoclonal autoantibodies specific for oxidized phospholipids or oxidized
phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density
lipoproteins.
J Clin Invest
1999;
103
: 117–128.
Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T.
14.
Involvement of beta
2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density
lipoprotein uptake by macrophages.
Clin Exp Immunol
1997;
107
: 569–573.
Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen
15.
K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of
carotid atherosclerosis.
Lancet
1992;
339
: 883–887.
Mironova MA, Klein RL, Virella GT, Lopes-Virella MF.
16.
Anti-modified LDL antibodies,
LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in
patients with type 2 diabetes.
Diabetes
2000;
49
: 1033–1041.
1Garrido-Sánchez L, Cardona F, García-Fuentes E, Rojo-Martínez G, Gómez-
17.
Zumaquero JM, Picón MJ,
et al.
Anti-oxidized low-density lipoprotein antibody
levels are associated with the development of type 2 diabetes mellitus.
Eur J Clin
Invest
2008;
38
: 615–621.
Matsha TE, Hassan MS, Kidd M, Erasmus RT. The 30-year cardiovascular risk profile
18.
of South Africans with diagnosed diabetes, undiagnosed diabetes, pre-diabetes
or normoglycaemia. The Bellville, South Africa pilot study.
Cardiovasc J Afr
2012;
23
(1): 5–11.
World Health Organization (WHO). International Society of Hypertension Guidelines
19.
for the Management of Hypertension.
J Hypertens
1999;
17
: 151–183.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus
20.
and its complications. Part 1: diagnosis and classification of diabetes mellitus
provisional report of a WHO consultation.
Diabet Med
1998;
15
: 539–553.
Pencina MJ, D’Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the
21.
30-year risk of cardiovascular disease: the framingham heart study.
Circulation
2009;
119
: 3078–3084.
Tinahones F
22.
J, Gómez-Zumaquero JM, Garrido-Sánchez L, García-Fuentes E, Rojo-
Martínez G, Esteva I,
et al
. Influence of age and sex on levels of anti-oxidized LDL
antibodies and anti-LDL immune complexes in the general population.
J Lipid Res
2005;
46
: 452–457.
Festa A, Kopp HP, Schernthaner G, Menzel EJ. Autoantibodies to oxidized
23.
low density lipoproteins in IDDM are inversely related to metabolic control and
microvascular complications.
Diabetologia
1998;
41
: 350–356.
Uusitupa MIJ, Niskanen L, Luoma J, Vilja P, Mercuri M, Rauramaa R, Yla-Hertualla S.
24.
Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease
in non-insulin-dependent diabetes mellitus.
Arterioscler Thromb Vasc Biol
1996;
16
: 1236–1242.
Korpinen E, Groop P-H, AkerblomHK, Vaarala O. Immune response to glycatedand
25.
oxidized LDL in IDDM patients with and without renal disease.
Diabetes Care
1997;
20
: 1168–1171.
Mironova M, Virella G, Virella-Lowell I, Lopes-Virella MF. Anti-modified LDL
26.
antibodies and LDL-containing immune complexes in IDDM patients and healthy
controls.
Clin Immunol Immunopathol
1997;
85
: 73–82.
Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T, Morooka S. Clinical
27.
significance of antibody against oxidized low density lipoprotein in patients with
atherosclerotic coronary artery disease.
J Am Coll Cardiol
2001;
37
: 775–779.
Wilson PW, Ben-Yehuda O, McNamara J, Massaro J, Witztum J, Reaven PD.
28.
Autoantibodies to oxidized LDL and cardiovascular risk: the Framingham Offspring
Study.
Atherosclerosis
2006;
189
: 364–368.
Fukumoto M, Shoji T, Emoto M, Kawagishi T, Okuno Y, Nishizawa Y.
29.
Antibodies
against oxidized LDL and carotid artery intima-media thickness in a healthy
population.
Arterioscler Thromb Vasc Biol
2000;
20
: 703–707.
Santos AO, Fonseca FA, Fischer SM, Monteiro CM, Brandão SA, Póvoa RM,
30.
et al.
High circulating autoantibodies against human oxidized low-density lipoprotein
are related to stable and lower titers to unstable clinical situation.
Clin Chim Acta
2009;
406
: 113–118.
Ridker PM. C-reactive protein: eighty years from discovery to emergence as a
31.
major risk marker for cardiovascular disease.
Clin Chem
2009;
55
: 209–215.
Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J,
32.
et al
.
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.
N
Engl J Med
2010;
362
: 800–811.
Shepperd C
33.
J, Eldridge AC, Mariner DC, McEwan M, Errington G, Dixon M. A
study to estimate and correlate cigarette smoke exposure in smokers in Germany
as determined by filter analysis and biomarkers of exposure.
Regul Toxicol
Pharmacol
2009;
55
: 97–109.
Benowitz NL. Cigarette smoking & cardiovascular disease pathophysiology and
34.
complications for treatment.
Prog Cardiovasc Dis
2003;
46
: 91–111.
Higdon J V, Frei B. 2003. Obesity and oxidative stress.
35.
Arterioscler,Thromb Vasc
Biol
23
: 365–367.
Weinbrenner T, Schroder H, Escurriol V, Fito M, Elosua R, Vila J,
36.
et al
. Circulating
oxidised LDL is associated with increased waist circumference independent of
body mass index in men and woman.
Am Soc Clin Nutr
2006;
83
: 30–35.
3 37. Wu R, Shoenfeld Y, Sherer Y, Patnaik M, Matsuura E, Gilburd B,
et al
. Anti-idiotypes
to oxidized LDL antibodies in intravenous immunoglobulin preparations – possible
immunomodulation of atherosclerosis.
Autoimmunity
2003;
36
: 91–97.
Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins.
38.
J Allergy
Clin Immunol
2010;
125
: S41–52.
Levitt NS, Katzenellenbogen JM, Bradshaw D, Hoffman MN, Bonnici F.
39.
The
prevalence and identification of risk factors for NIDDM in urban Africans in Cape
Town, South Africa.
Diabetes Care
1993;
16
: 601–607.
Miller MA, Strazzullo P, Karanam S, Cappuccio FP.
40.
Ethnic variation in levels of
circulating IgG autoantibodies to oxidised low-density lipoprotein.
Atherosclerosis
2009;
203
: 126–136.
It's the
shell that
makes
safer.
Safety-Coated
R
81mg
The ORIGINAL low dose aspirin
for optimum cardio-protection
Hp
Each tablet contains Aspirin 81mg. Reg.No.: 29/2.7/0767
Pharmafrica (Pty) Ltd, 33 Hulbert Road, New Centre, Johannesburg 2001
Under licence from Goldshield Pharmaceuticals Ltd. U.K.